The short-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines among healthcare workers: a systematic literature review and meta-analysis

Abstract Objective: Healthcare workers (HCWs) are at risk of COVID-19 due to high levels of SARS-CoV-2 exposure. Thus, effective vaccines are needed. We performed a systematic literature review and meta-analysis on COVID-19 short-term vaccine effectiveness among HCWs. Methods: We searched PubMed, CINAHL, EMBASE, Cochrane Central Register of Controlled Trials, Scopus, and Web of Science from December 2019 to June 11, 2021, for studies evaluating vaccine effectiveness against symptomatic COVID-19 among HCWs. To meta-analyze the extracted data, we calculated the pooled diagnostic odds ratio (DOR) for COVID-19 between vaccinated and unvaccinated HCWs. Vaccine effectiveness was estimated as 100% × (1 − DOR). We also performed a stratified analysis for vaccine effectiveness by vaccination status: 1 dose and 2 doses of the vaccine. Results: We included 13 studies, including 173,742 HCWs evaluated for vaccine effectiveness in the meta-analysis. The vast majority (99.9%) of HCWs were vaccinated with the Pfizer/BioNTech COVID-19 mRNA vaccine. The pooled DOR for symptomatic COVID-19 among vaccinated HCWs was 0.072 (95% confidence interval [CI], 0.028–0.184) with an estimated vaccine effectiveness of 92.8% (95% CI, 81.6%–97.2%). In stratified analyses, the estimated vaccine effectiveness against symptomatic COVID-19 among HCWs who had received 1 dose of vaccine was 82.1% (95% CI, 46.1%–94.1%) and the vaccine effectiveness among HCWs who had received 2 doses was 93.5% (95% CI, 82.5%–97.6%). Conclusions: The COVID-19 mRNA vaccines are highly effective against symptomatic COVID-19, even with 1 dose. More observational studies are needed to evaluate the vaccine effectiveness of other COVID-19 vaccines, COVID-19 breakthrough after vaccination, and vaccine efficacy against new variants.

[1]  C. del Rio,et al.  Confronting the Delta Variant of SARS-CoV-2, Summer 2021. , 2021, JAMA.

[2]  O. Mor,et al.  Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[3]  L. Nolen,et al.  COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[4]  F. Fitzpatrick,et al.  Impact of first dose of BNT162b2 vaccine on COVID-19 infection among healthcare workers in an Irish hospital , 2021, Irish Journal of Medical Science (1971 -).

[5]  James C. Crosby,et al.  Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[6]  L. Vimercati,et al.  BNT162b2 mRNA Covid-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection: a preliminary report , 2021, The Journal of infectious diseases.

[7]  Samuel M. Brown,et al.  Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[8]  E. Sprecher,et al.  Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. , 2021, JAMA.

[9]  M. Lombardo,et al.  Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy. , 2021, Journal of Infection.

[10]  E. Neufeld,et al.  Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce. , 2021, JAMA.

[11]  D. Thoroughman,et al.  COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program — Kentucky, March 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[12]  Early observations on the impact of a healthcare worker COVID-19 vaccination programme at a major UK tertiary centre , 2021, Journal of Infection.

[13]  J. Sánchez-Payá,et al.  [Effectiveness of the first dose of BNT162b2 vaccine to preventing covid-19 in healthcare personnel.] , 2021, Revista Española de Salud Pública.

[14]  H. Chu,et al.  Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  R. Darnell,et al.  Vaccine Breakthrough Infections with SARS-CoV-2 Variants , 2021, The New England journal of medicine.

[16]  G. Bearman,et al.  Riding the Third Wave: How an Academic Medical Center Reduced Covid-19 Infections in Health Care Workers , 2021, Nejm Catalyst Innovations in Care Delivery.

[17]  Andrew L. Phillips,et al.  Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[18]  P. Pezzotti,et al.  Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[19]  Matan J. Cohen,et al.  BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers , 2021, The New England journal of medicine.

[20]  L. Danon,et al.  Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study , 2021, BMJ.

[21]  D. Ho,et al.  Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.

[22]  M. Hernán,et al.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.

[23]  R. Samworth,et al.  Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection , 2021, eLife.

[24]  Y. Kreiss,et al.  Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients , 2021, The Lancet.

[25]  M. Edelstein,et al.  Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[26]  M. Biggerstaff,et al.  SARS-CoV-2 Transmission From People Without COVID-19 Symptoms , 2021, JAMA network open.

[27]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[28]  J. Pell,et al.  Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants , 2020, Occupational and Environmental Medicine.

[29]  A. Pollard,et al.  What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 , 2020, The Lancet Infectious Diseases.

[30]  Lindsay N. Carpp,et al.  Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials , 2020, Annals of Internal Medicine.

[31]  David A. Drew,et al.  Risk of COVID-19 among frontline healthcare workers and the general community: a prospective cohort study , 2020, medRxiv.

[32]  Eric H. Y. Lau,et al.  Temporal dynamics in viral shedding and transmissibility of COVID-19 , 2020, Nature Medicine.

[33]  S. Ge,et al.  Assessment of study quality. , 2015 .

[34]  E. Perencevich,et al.  Accuracy of administrative code data for the surveillance of healthcare-associated infections: a systematic review and meta-analysis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[36]  Johannes B Reitsma,et al.  Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. , 2005, Journal of clinical epidemiology.

[37]  A. Harris,et al.  A systematic review of quasi-experimental study designs in the fields of infection control and antibiotic resistance. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[39]  N. Black,et al.  The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. , 1998, Journal of epidemiology and community health.

[40]  Ping Li,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020 .

[41]  Heinz Holling,et al.  Meta-Analysis of Diagnostic Accuracy with mada , 2015 .

[42]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.